AGL 38.55 Decreased By ▼ -0.01 (-0.03%)
AIRLINK 200.83 Decreased By ▼ -6.94 (-3.34%)
BOP 10.19 Increased By ▲ 0.13 (1.29%)
CNERGY 6.57 Decreased By ▼ -0.51 (-7.2%)
DCL 9.68 Decreased By ▼ -0.31 (-3.1%)
DFML 39.90 Decreased By ▼ -1.24 (-3.01%)
DGKC 97.67 Decreased By ▼ -5.79 (-5.6%)
FCCL 35.10 Decreased By ▼ -1.25 (-3.44%)
FFBL 86.00 Decreased By ▼ -5.59 (-6.1%)
FFL 13.95 Decreased By ▼ -0.65 (-4.45%)
HUBC 130.45 Decreased By ▼ -8.98 (-6.44%)
HUMNL 14.00 Decreased By ▼ -0.10 (-0.71%)
KEL 5.64 Decreased By ▼ -0.33 (-5.53%)
KOSM 7.30 Decreased By ▼ -0.56 (-7.12%)
MLCF 45.60 Decreased By ▼ -1.68 (-3.55%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 221.50 Decreased By ▼ -1.16 (-0.52%)
PAEL 38.45 Increased By ▲ 0.34 (0.89%)
PIBTL 8.96 Decreased By ▼ -0.31 (-3.34%)
PPL 196.85 Decreased By ▼ -9.00 (-4.37%)
PRL 38.85 Decreased By ▼ -1.00 (-2.51%)
PTC 25.60 Decreased By ▼ -1.02 (-3.83%)
SEARL 104.50 Decreased By ▼ -5.74 (-5.21%)
TELE 9.06 Decreased By ▼ -0.17 (-1.84%)
TOMCL 36.41 Decreased By ▼ -1.80 (-4.71%)
TPLP 13.64 Decreased By ▼ -0.13 (-0.94%)
TREET 25.20 Decreased By ▼ -1.25 (-4.73%)
TRG 58.10 Decreased By ▼ -2.44 (-4.03%)
UNITY 33.55 Decreased By ▼ -0.59 (-1.73%)
WTL 1.73 Decreased By ▼ -0.15 (-7.98%)
BR100 11,896 Decreased By -402.5 (-3.27%)
BR30 37,383 Decreased By -1494.9 (-3.85%)
KSE100 111,070 Decreased By -3790.4 (-3.3%)
KSE30 34,909 Decreased By -1287 (-3.56%)

US FDA

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon
World

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

  • The approval is highly anticipated after the drugmaker said in March the vaccine was found to be safe, effective and produced a robust antibody responses in 12- to 15-year-olds in a clinical trial.
  • The vaccine has already been cleared in the United States for those aged 16 and above.
Published 05 May, 2021 06:26pm
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
Business & Finance

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Published 16 Apr, 2021 05:45pm